Company intelligence / Profile preview

Utopia Therapeutics

Hyderabad, Telangana, India

Ownership: Private
Development stage: Other

Overview

Utopia Therapeutics is an early-stage biotech startup, founded in 2024 in India, developing first-in-class therapies for chronic metabolic diseases, primarily obesity and non-alcoholic fatty liver disease (NAFLD). Their lead candidate, UT009, is a one-shot vaccine targeting lipid-associated antigens to reduce fat accumulation and improve metabolic health, with animal studies showing over 40% reduction in visceral fat and improvement in fatty liver within 8 weeks. The company is preparing for Investigational New Drug (IND) filing in Q4 2025 and subsequent Phase I trials.

Therapeutic areas: GastroenterologyEndocrinology
Modalities: VaccineRegenerative therapy
Industry: Biotech

Partnerships

Whale Tank Biocatalyst Fund (investor)Federation of Asian Biotech Associations (FABA)BIRACABLE

Beyond the preview

Go deeper on Utopia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Utopia Therapeutics.

Explore the full profile